DEA Extends Telehealth Prescribing Rules – Advocates Praise Move

“`html

DEA Extends Telemedicine Prescribing Flexibilities Through 2026

The Drug Enforcement Management (DEA) has extended temporary flexibilities allowing for the remote prescribing of controlled substances via telehealth for another year, averting potential disruptions to patient care and providing time to establish permanent regulations.

The DEA’s decision,announced ahead of the scheduled expiration of current rules,extends the allowances through December 31,2026.This marks the fourth extension of thes telemedicine prescribing flexibilities, initially implemented during the height of the COVID-19 pandemic to broaden access to healthcare.

The temporary rules permitted the prescribing of controlled substances without requiring an initial in-person medical examination. According to the DEA’s statement in the Federal Register, the extension is crucial to prevent patients from experiencing abrupt gaps in treatment. Allowing the flexibilities to lapse would have reverted prescribing practices to pre-pandemic restrictions. The additional time will also enable the agency to finalize a thorough set of regulations, facilitate a smooth transition for both patients and providers, and ensure adequate time for compliance.

Did you know?-The DEA first implemented these telehealth prescribing flexibilities in response to the COVID-19 pandemic, aiming to maintain healthcare access during lockdowns and social distancing measures.

Advocacy groups within the telehealth industry have lauded the extension. ATA Action, the public policy arm of the American Telemedicine Association (ATA), expressed its gratitude for the continued access to care.

“This one-year extension is a major relief for patients and healthcare providers, restoring certainty and avoiding treatment gaps for millions of Americans,” stated Alexis Apple, deputy executive director of ATA Action and vice president of federal affairs at the ATA. “The remote prescribing of controlled substances waiver…has proven to be a lifeline for patients by expanding access to care, reducing treatment delays, and improving outcomes. This critically significant waiver must be preserved continuously until a permanent policy is enacted.”

The ATA is particularly advocating for a special registration process specifically designed for clinicians who wish to virtually prescribe controlled substances. This framework, they argue, would balance responsible patient care with the DEA’s need to prevent misuse.

“We continue to support a permanent Special Registration framework that enables responsible patient care and equips the DEA with appropriate tools to prevent misuse,” Apple added. “We also encourage the DEA to seek provider feedback when developing safeguards to reduce diversion, improve access to essential prescriptions for mental health, substance use disorder, and other chronic conditions, and prioritize patient safety. ATA Action believes clinical decisions should remain the judgment of qualified medical professionals, supported by regulatory frameworks that protect patients and promote responsible care.”

Pro tip-Clinicians prescribing controlled substances via telehealth should document all encounters thoroughly, including the virtual examination and rationale for prescribing, to ensure compliance.

The Alliance for Connected Care,another prominent telehealth advocacy association,echoed these sentiments. Chris Adamec, the Alliance’s executive director, stated, “we applaud DEA for acting to continue access to care for the millions of patients who depend on telehealth for essential medications. However, this should be the last time these Americans come within days of losing access to the care they need.”

Why did this happen? The DEA extended the temporary flexibilities to avoid disruptions in patient care and to allow time to create permanent regulations for telehealth prescribing. These flexibilities were initially put in place during the COVID-19 pandemic to increase access to healthcare.

Who is involved? Key players include the Drug Enforcement Administration (DEA), telehealth advocacy groups like ATA Action and the Alliance for Connected Care, healthcare providers, and millions of patients who rely on telehealth for controlled substance prescriptions.

what changed? the DEA extended the temporary rules allowing remote prescribing of controlled substances via telehealth through December 31, 2026.This is the fourth extension since the initial implementation during the pandemic.

How did it end? The DEA announced the extension in the Federal Register, averting an immediate return to pre-pandemic restrictions.